China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC – Free Report)’s stock is scheduled to reverse split on Monday, October 26th. The 1-100 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, October 25th.
China SXT Pharmaceuticals Stock Down 34.2%
NASDAQ SXTC traded down $0.03 during trading hours on Thursday, reaching $0.05. 55,565,881 shares of the company traded hands, compared to its average volume of 6,650,193. China SXT Pharmaceuticals has a 12 month low of $0.05 and a 12 month high of $83,758.80. The company has a current ratio of 7.94, a quick ratio of 7.76 and a debt-to-equity ratio of 0.02. The company has a 50 day moving average of $2.22 and a two-hundred day moving average of $89.02.
Analyst Upgrades and Downgrades
Several analysts recently weighed in on SXTC shares. Weiss Ratings raised China SXT Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Wednesday. Wall Street Zen upgraded China SXT Pharmaceuticals to a “sell” rating in a research note on Saturday, August 22nd. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, China SXT Pharmaceuticals currently has a consensus rating of “Sell”.
Get Our Latest Research Report on SXTC
About China SXT Pharmaceuticals
China SXT Pharmaceuticals, Inc (NASDAQ: SXTC) is a pharmaceutical company based in Taizhou, Jiangsu Province, China. The company develops, manufactures and sells traditional Chinese medicine products, serving customers primarily in the Chinese market.
Its product portfolio includes prescription and over-the-counter traditional Chinese medicines, as well as health-related products and dietary supplements. The company’s operations encompass the preparation of herbal ingredients and the production, marketing and distribution of finished traditional Chinese medicine products.
China SXT Pharmaceuticals was established in 2005 and completed its initial public offering on the Nasdaq Capital Market in 2019.
Read More
- Five stocks we like better than China SXT Pharmaceuticals
- Is Texas Instruments Setting Up for Its Next Big Breakout?
- Pegasystems’ Q3 Miss Exposed the Problem Standing Between AI and Cash Flow
- Lam Research’s Earnings Beat Wasn’t the Real Story—Its 2027 Outlook Was
- Tesla’s Flying-Car Hype Hits an Earnings Reality Check
Receive News & Ratings for China SXT Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China SXT Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
